TREM2 STABILIZING ANTIBODIES
VE6142019000565SUndetermined Publication Date: 2022-02-17NOVARTIS AG
View PDF 0 Cites 0 Cited by
Patent Information
- Authority / Receiving Office
- VE · VE
- Patent Type
- Designs
- Current Assignee / Owner
- NOVARTIS AG
- Filing Date
- 2019-10-10
- Publication Date
- 2022-02-17
Need to check novelty before this filing date? Find Prior Art
Description
The present invention provides antibodies that bind to and stabilize the human activation receptor protein expressed in myeloid cells 2 (TREM2), and methods for using these antibodies.